RCKT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rocket Pharmaceuticals Inc. (RCKT) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 investment range at this time. While there are positive catalysts such as FDA approval for Kresladi and favorable analyst ratings, the company's financial performance is weak, with significant losses and no revenue growth. Additionally, there are no strong trading signals or recent influential trades to support immediate action. Holding off for now is advisable.
The technical indicators are mixed. The MACD is positive, suggesting potential upward momentum, but the RSI is neutral, indicating no clear signal. The moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its pivot level of 3.769. However, the pre-market price increase of 1.36% is modest and does not strongly indicate a breakout.
FDA approval for Kresladi, a significant milestone for Rocket Pharmaceuticals. Analysts have raised price targets and reiterated positive ratings, with some highlighting the potential monetization of a rare pediatric disease priority review voucher worth $100M-$200M. The approval also reflects strong execution by management.
The company's financial performance is weak, with a significant net income loss of -$42.54M in Q4 2025 and a declining EPS of -38.71% YoY. There is no revenue growth, and the gross margin remains at 0%. Additionally, there is no recent news or significant trading activity by hedge funds, insiders, or influential figures.
In Q4 2025, Rocket Pharmaceuticals reported no revenue growth (0% YoY), a net income loss of -$42.54M (-29.49% YoY), and a drop in EPS to -0.38 (-38.71% YoY). The gross margin remains at 0%, indicating no profitability.
Analysts are generally positive on Rocket Pharmaceuticals. Recent ratings include price target increases from firms like BofA ($9), Leerink ($11), LifeSci Capital ($9), Wedbush ($16), and Cantor Fitzgerald ($10). The FDA approval for Kresladi has been well-received, though some analysts noted disappointment in the lack of pricing commentary and updated timelines.
